<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122847</url>
  </required_header>
  <id_info>
    <org_study_id>GRO-BONE1</org_study_id>
    <nct_id>NCT03122847</nct_id>
  </id_info>
  <brief_title>Glucocorticoids and Bone in Graves' Ophthalmopathy</brief_title>
  <official_title>The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torben Harsløf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous use of systemic glucocorticoids decreases bone mineral density and increases
      fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous
      glucocorticoid. The investigators aim at investigating whether this treatment regimen also
      affects bone metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic glucocorticoid increases bone resorption and decreases bone formation and thereby
      decreases bone mineral density and increases fracture risk. This effect is evident with a
      daily dose of 5 mg for three months or an accumulated dose of 450mg. There is, however, less
      evidence that intermittent use of glucocorticoids is harmful to bone.

      Graves orbitopathy is treated with a weekly infusion of the glucocorticoid methylprednisolone
      and the accumulated dose over a 12-week course sums up to 4,500mg.

      The investigators therefore want to investigate if that treatment regimen affects bone
      turnover, bone mineral density, or bone structure in 30 patients with Graves' orbitopathy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine bone mineral density</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in lumbar spine bone mineral density from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Femoral neck bone mineral density</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in femoral neck bone mineral density from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hip bone mineral density</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in total hip bone mineral density from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in bone turnover measured by the biochemical markers CTx and P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone structure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in bone structure measured by high-resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graves Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Intravenous methylprednisolone</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples stored at -80C for batch analysis at study completion
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        30 adult patients with Graves' Ophthalopathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Graves Ophthalmopathy that requires treatment with intra-venous methylprednisolone

        Exclusion Criteria:

          -  Treatment with osteoporosis medication

          -  Hyperparathyroidism

          -  Hypoparathyroidism

          -  Vitamin D &lt; 20mmol/L

          -  eGFR &lt; 30

          -  Liver disease

          -  Peroral treatment with glucocorticoids within last three months prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Torben Harsløf, MD, PhD</last_name>
    <phone>+4578467605</phone>
    <email>torbhars@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Ebbehøj, MD, PhD</last_name>
    <phone>+4578467605</phone>
    <email>eva.ebbehøj@aarhus.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <state>Central Denmark Region</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torben Harsløf, MD, PhD</last_name>
      <email>torbhars@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Eva Ebbehøj, MD, PhD</last_name>
      <email>eva.ebbehoj@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000C</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Nielsen, MD, PhD</last_name>
      <email>frostnielsen@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Torben Harsløf</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

